Early stage molecular diagnostics company NuProbe has announced the closing of a $11 million Series A round of funding led by Sequoia Capital China and Serica Partners to continue its development of ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases.
Boston -based NuProbe has closed an $11m series A funding round, led by Sequoia Capital China and Serica Partners . Molecular diagnostic specialist NuProbe has developed a highly sensitive, non-invasive blood test enabling the early detection of cancer and other diseases. The latest investment will be used to continue clinical trials and for work on developing a commercial product, as well as to expand staffing at NuProbe US and China offices. Private US biotechnology firms received $ $11m of Chinese investment during Q1 2018 , according to Serica Partners .